Popular Articles

Multiple Myeloma Research Consortium (MMRC) Activates Clinical Trials 30-40 Percent Faster Than Industry Standard
The Multiple Myeloma Research Consortium (MMRC), an innovative research model comprised of a network of 15 academic Member Institutions across North America and leadership in Norwalk, Connecticut, announced preliminary data from an analysis showing that clinical trials opened through its clinical trials network were activated 30 to 40 percent faster than comparable clinical trials in oncology. Based on the implementation of specific business solutions, particularly scientific leadership, standardized clinical contracts and on-site project management res, the MMRC has been able to decrease by an average of 100 days the time from the development and finalization of the trial"s protocol to actual patient enrollment.
generic viagra online
Tongue Drive System Enables Quadriplegics To Operate Powered Wheelchair In Clinical Trial
An assistive technology that enables individuals to maneuver a powered wheelchair or control a mouse cursor using simple tongue movements can be operated by individuals with high-level spinal cord injuries, according to the results of a recently completed clinical trial.
plastic surgery before after
News of the day
One Doctor's View: Electronic Medical Records Work Well
Doctors increasingly use email and electronic medical records to improve health care. In an essay in the Los Angeles Times, Rahul Parikh writes about his own experience at a Kaiser Permanente facility in Northern California where they implemented an electronic medical record system in 2006: "...notes, orders and prescriptions are clear and contiguous. There"s no waiting for paperwork. And if a patient of mine shows up in another office across town (remember, Kaiser is an integrated system -- we all share the same computer network), a doctor whom I have never met can see what I"ve written, my patient"s list of problems and what I"ve done for the patient in the past before he or she even sets foot in the room to talk to the patient. Such record systems can alert us to possible medication errors or dangerous drug interactions. They can continuously be updated to identify best practices. And they talk to patients as well, allowing them to access past-visit information and immunization records and to make appointments and send e-mails to their doctor."
Diagnostics

Biotech Factories Created From Bacteria

High-throughput sequencing has turned biologists into voracious genome readers, enabling them to scan millions of DNA letters, or bases, per hour. When revising a genome, however, they struggle, suffering from serious writer"s block, exacerbated by outdated cell programming technology. Labs get bogged down with particular DNA sentences, tinkering at times with subsections of a single gene ad nauseam before moving along to the next one. A team has finally overcome this obstacle by developing a new cell programming method called Multiplex Automated Genome Engineering (MAGE). Published online in Nature, the platform promises to give biotechnology, in particular synthetic biology, a powerful boost. Led by a pair of researchers in the lab of Harvard Medical School Professor of Genetics George Church, the team rapidly refined the design of a bacterium by editing multiple genes in parallel instead of targeting one gene at a time. They transformed self-serving E. coli cells into efficient factories that produce a desired compound, accomplishing in just three days a feat that would take most biotech companies months or years. "We initiated the project to close the gap between DNA sequencing technology and cell programming technology," explains graduate student Harris Wang, the paper"s co-first author. "The goal was to use information gleaned from genetics and genomics to rapidly engineer new functions and improve existing functions in cells," adds postdoctoral researcher Farren Isaacs, the other first author. "We wanted to develop a new tool and demonstrate how to apply it; we were determined to hand labs a hammer and a nail." The key was to break free of linear genetic engineering techniques and move beyond the serial manipulation of single genes. The researchers selected a harmless strain of the intestinal nemesis E. coli and added a few genes to its solitary circular chromosome, coaxing the organism to produce lycopene, a powerful antioxidant that occurs naturally in tomatoes and other vegetables. Now they could focus on tweaking the cells to increase the yield of this compound. Traditionally, labs would accomplish this type of transformation by using recombinant DNA technology, also known as gene cloning, a complicated technique that involves isolating, breaking up, reassembling, and then reinserting genes. The Church lab researchers took a different approach, blending an engineer"s logic with a biologist"s appreciation for complexity. "Genes function in teams, not in isolation," says Wang. "Cloning often encourages us to ignore the interdependence of genes and oversimplify the cellular system. We might forget, for example, that one mutation can strengthen or weaken the effects of another mutation." "It"s nearly impossible to predict which combinations of mutations will confer the desired behavior," explains Isaacs. "Biology is so complex that we don"t know the optimal solution." So the team retooled evolution to generate genetic diversity at an unprecedented rate, increasing the odds of finding cells with desirable properties. The E. coli bacterium contains approximately 4,500 genes. The team focused on 24 of these - honing a pathway with tremendous potential - to increase production of the antioxidant, optimizing the sequences simultaneously. They took the 24 DNA sequences, divided them up into manageable 90-letter segments, and modified each, generating a suite of genetic variants. Next, armed with specific sequences, the team enlisted a company to manufacture thousands of unique constructs. The team was then able to insert these new genetic constructs back into the cells, allowing the natural cellular machinery to absorb this revised genetic material. Some bacteria ended up with one construct, some ended up with multiple constructs. The resulting pool contained an assortment of cells, some better at producing lycopene than others. The team extracted the best producers from the pool and repeated the process over and over to further hone the manufacturing machinery. To make things easier, the researchers automated all of these steps. "We accelerated evolution, generating as many as 15 billion genetic variants in three days and increasing the yield of lycopene by 500 percent," Harris says. "Can you imagine how long it would take to generate 15 billion genetic variants with traditional cloning techniques? It would take years." The pathway the team refined plays a role in the synthesis of many valuable compounds, ranging from hormones to antibiotics, so the reprogrammed bacteria can be used for a variety of purposes. In addition, the MAGE platform itself unlocks new possibilities. "We decided to engineer in the context of biology, embracing evolution rather than trying to fit a square peg in a round hole," says Church. "This automated, multiplex technology will allow labs to engineer entire pathways and genomes and take cell programming to a whole new level." This research is funded by NSF, DOE, DARPA, the Wyss Institute for Biologically Inspired Engineering, NIH and NDSEG. Alyssa Kneller Harvard Medical School


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):